𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Pilot study of PD-0325901 in previously treated patients with advanced melanoma, breast cancer, and colon cancer

✍ Scribed by Peter D. Boasberg; Charles H. Redfern; Gregory A. Daniels; David Bodkin; Chris R. Garrett; Alejandro D. Ricart

Publisher
Springer
Year
2011
Tongue
English
Weight
251 KB
Volume
68
Category
Article
ISSN
0344-5704

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Adriamycin, vincristine, dibromodulcitol
Adriamycin, vincristine, dibromodulcitol, and hexamethylmelamine in advanced previously treated breast cancer: An ECOG pilot study
✍ Taylor, Samuel G. ;Wolter, Janet πŸ“‚ Article πŸ“… 1981 πŸ› John Wiley and Sons 🌐 English βš– 155 KB

## Abstract A combination of adriamycin, vincristine, dibromodulcitol, and hexamethylmelamine was piloted in patients with advanced breast cancer who had failed prior CMFP chemotherapy, as a part of ongoing trials by the Eastern Cooperative Oncology Group to improve second‐line chemotherapy for thi

Trimetrexate in untreated and previously
Trimetrexate in untreated and previously treated patients with metastatic breast cancer: A cancer and leukemia group b study
✍ Dawson, Nancy A. ;Costanza, Mary E. ;Korzun, Ann H. ;Clamon, Gerald H. ;Pollak, πŸ“‚ Article πŸ“… 1991 πŸ› John Wiley and Sons 🌐 English βš– 554 KB

Twenty-two patients with previously untreated metastatic breast cancer and nineteen patients with refractory metastatic breast cancer were treated with trimetrexate (TMTX). Patients received TMTX 8 mg/m2/day if previously treated or 12 mg/m2/day if previously untreated, both given by intravenous bol

Vincristine, doxorubicin and mitomycin (
Vincristine, doxorubicin and mitomycin (VAM) in patients with advanced breast cancer previously treated with cyclophosphamide, methotrexate and fluorouracil (CMF)
✍ Sharon K. Shipp; Hyman B. Muss; Mary Alice Westrick; M. Robert Cooper; V. Jackso πŸ“‚ Article πŸ“… 1983 πŸ› Springer 🌐 English βš– 383 KB

Thirty-six evaluable patients with advanced breast cancer who had failed prior CMF therapy [15 (42%) as adjuvant treatment and 21 (58%) for advanced disease] were treated with a combination of vincristine, doxorubicin, and mitomycin (VAM). There was one CR and 10 PR, giving a response rate of 31% (P